VBI Vaccines (VBIV) Given Consensus Rating of “Hold” by Brokerages

Shares of VBI Vaccines (NASDAQ:VBIV) have earned a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $10.50.

Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. BidaskClub lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Finally, Noble Financial reissued a “buy” rating on shares of VBI Vaccines in a report on Friday, March 23rd.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in VBI Vaccines during the 3rd quarter worth $1,329,000. BVF Inc. IL acquired a new stake in VBI Vaccines during the 4th quarter worth $13,237,000. General American Investors Co. Inc. acquired a new stake in VBI Vaccines during the 4th quarter worth $2,562,000. The Manufacturers Life Insurance Company acquired a new stake in VBI Vaccines during the 4th quarter worth $126,000. Finally, Perceptive Advisors LLC boosted its stake in VBI Vaccines by 47.2% during the 4th quarter. Perceptive Advisors LLC now owns 9,665,843 shares of the biopharmaceutical company’s stock worth $41,273,000 after purchasing an additional 3,100,000 shares during the last quarter. 48.33% of the stock is owned by institutional investors.

NASDAQ VBIV traded down $0.14 on Friday, hitting $3.31. The company had a trading volume of 121,187 shares, compared to its average volume of 118,635. The firm has a market cap of $209.99, a PE ratio of -4.48 and a beta of 2.04. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.26 and a current ratio of 5.32. VBI Vaccines has a 12-month low of $3.04 and a 12-month high of $5.10.

COPYRIGHT VIOLATION WARNING: This story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2018/04/19/vbi-vaccines-vbiv-given-consensus-rating-of-hold-by-brokerages.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply